Skip to main content
SpringerLink
Log in

Preoperative infliximab treatment in patients with ulcerative and indeterminate colitis does not increase rate of conversion to emergent and multistep abdominal surgery

  • Original Article
  • Published:
International Journal of Colorectal Disease Aims and scope Submit manuscript

Abstract

Introduction

A recent study has raised concerns that infliximab treatment, by postpoing surgery for ulcerative and indeterminate colitis patients, may result in a greater need for high-risk emergent or multistep surgical procedures (subtotal colectomies). Our aim was to assess whether infliximab exposure affects rates of subotal colectomy in a large cohort of patients.

Methods

We evaluated 171 consecutive patients with ulcerative or indeterminate colitis who had a total proctocolectomy or a subtotal colectomy between 1993 and 2006 for symptoms of unremitting disease. Forty-four patients (25.7%) received infliximab prior to surgery. We compared the surgical procedures employed on these 44 patients to the surgical procedures employed on the 127 non-infliximab patients, using Fisher’s exact or Student’s t test.

Results

Infliximab exposure did not appear to affect the rate of emergent surgery (4.5% vs 4.4%, p = 0.98), rate of subtotal colectomy (19.2% vs. 18.0%, p = 0.99), or rate of ileoanal J pouch reconstruction (53.8% vs. 62%, p = 0.98). Nor did it affect intraoperative findings of perforation, toxic megacolon, and active disease. The infliximab and non-infliximab cohorts were similar in age, Charlson Comorbidity Index, concomitant steroid use, and albumin levels, although infliximab patients had higher rates of concomitant exposure to 6-mercaptopurine (34.1% vs 16.6%, p = 0.02) and azathioprine (40.9% vs 22.6%, p = 0.02).

Conclusion

Infliximab does not appear to increase rates of emergent surgery or multistep procedures in patients undergoing treatment for ulcerative or indeterminative colitis at our institution.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE (2005) Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 128(4):862–869

    Article  CAS  PubMed  Google Scholar 

  2. Mor IJ, Vogel JD, Moreira Ada L, Shen B, Hammel J, Remzi FH (2008) Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum 51(8):1202–1207 discussion 1207-1210

    Article  CAS  PubMed  Google Scholar 

  3. Selvasekar CR, Cima RR, Larson DW et al (2007) Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 204(5):956–962 discussion 962-953

    Article  PubMed  Google Scholar 

  4. Galandiuk S (2007) Discussion. J Am Coll Surg 204:962

    Article  Google Scholar 

  5. Hall WH, Ramachandran R, Narayan S, Jani AB, Vijayakumar S (2004) An electronic application for rapidly calculating Charlson comorbidity score. BMC Cancer 4:94

    Article  PubMed  Google Scholar 

  6. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM (2003) How to measure comorbidity, a critical review of available methods. J Clin Epidemiol 56(3):221–229

    Article  PubMed  Google Scholar 

  7. Remicade Package Insert. http://www.remicade.com/remicade/assets/HCP-PPI.pdf

  8. Rutgeerts P, Sandborn WJ, Feagan BG et al (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353(23):2462–2476

    Article  CAS  PubMed  Google Scholar 

  9. Lichtenstein GR, Yan S, Bala M, Hanauer S (2004) Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 99(1):91–96

    Article  PubMed  Google Scholar 

  10. Hancock L, Windsor AC, Mortensen NJ (2006) Inflammatory bowel disease: the view of the surgeon. Colorectal Dis 8(Suppl 1):10–14

    Article  PubMed  Google Scholar 

  11. Schluender SJ, Ippoliti A, Dubinsky M et al (2007) Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum 50(11):1747–1753

    Article  PubMed  Google Scholar 

Download references

Disclosures

None.

Author information

Authors and Affiliations

  1. MGH Crohn’s & Colitis Center, Harvard Medical School, Boston, MA, USA

    Liliana Bordeianou, Hiroko Kunitake, Paul Shellito & Richard Hodin

  2. Department of Surgery, Massachusetts General Hospital, 15 Parkman Street, ACC 460, Boston, MA, 02114, USA

    Liliana Bordeianou, Hiroko Kunitake, Paul Shellito & Richard Hodin

Authors
  1. Liliana Bordeianou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroko Kunitake
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul Shellito
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Richard Hodin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Liliana Bordeianou.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bordeianou, L., Kunitake, H., Shellito, P. et al. Preoperative infliximab treatment in patients with ulcerative and indeterminate colitis does not increase rate of conversion to emergent and multistep abdominal surgery. Int J Colorectal Dis 25, 401–404 (2010). https://doi.org/10.1007/s00384-009-0800-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00384-009-0800-5

Keywords

Search

Navigation